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The klnins are a  group of closely  related polypepfides including  bradykinin and 
methionyl bradykinin, which  are potent agents in  enhancing vascular permeability, 
contracting smooth muscle,  and dilating small blood vessels  (1). These polypeptides 
are formed in plasma and, probably, in extravascular tissues from a protein substrate, 
or substrates, kininogen,  by the action of a number of proteolytic enzymes (2). Among 
these enzymes are the kallikreins,  comprising  a group of similar yet distinctly differ- 
ent enzymes present in plasma, various tissues such as the pancreas and salivary glands, 
and in urine (3). The kallikreins exist in an inactive precursor form, the prokallikreins 
or kallikreinogens  and are activated by a  step-wise,  sequential process,  which  is in- 
completely understood (2). 
In 1950, Beraldo demonstrated an increase  in kinin in the blood of dogs following 
anaphylactic  shock  (4).  More  recently,  Brocldehurst  reported  that  kinin  can  be 
detected in the blood of guinea pigs, rats, and rabbits within 5 rain after intravenous 
induction of anaphylaxis (5).  Other workers have since studied the participation of 
kinin in anaphylactic shock of various species (6-13). 
Brocklehurst and Lahiri have also demonstrated, in experiments with the isolated 
perfused guinea pig lung, that challenge with antigen led to the prompt appearance of 
kinin-forming activity (kallikrein)  in the effluent.  Kinin was absent, presumably be- 
cause of the lack of kininogen in the perfusion preparation. The highly active kinin 
destroying enzyme, kininase,  was present in the perfusate (14). 
In these experiments, we have used a  similar system of perfused sensitized 
guinea pig lung to study the nature of the kallikrein activity which is produced 
during  anaphylaxis.  We  have  compared  its  properties  to  those  of  plasma 
kallikrein,  and have begun the study of the mechanism of activation of kalli- 
krein in the lung by the antigen-antibody reaction. 
Materials and Methods 
All glassware used in the bioassay was siliconized. 
Standard Solutions for  Bioassay.--Braxlyklnin standards  (Calbiochem Company,  Los 
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Angeles)  were prepared in 0.25% casein,  in dilutions of 100 nanograms per mi, and kept at 
-20°C for 6 months. 
Human  Urinary  KaUikrein.--Human  urinary  kallikrein  was  supplied  by  Dr.  Marion 
Webster, National Institutes of Health, Bethesda, Maryland. 
Human  Plasma Kallikrein  and Pf/dil.--Human plasma kallikrein and human Pf/dil were 
supplied by Dr. David McConnell, Waiter Reed Army Institute of Research. 
Guinea Pig Plasma Kallikrein.--Gtfinea  pig plasma kaUikrein was prepared by elution of 
guinea pig serum from DEAE cellulose by 0.005 ~  sodium phosphate buffer,  pH 8.10, exactly 
as described for the preparation of human plasma kallikrein (15). 
Inldbitors.--Soybean  trypsin inhibitor (SBTI), five times crystallized, was obtained from 
Mann Research Laboratories, New York City. 
Diisopropylfluorophosphate  (DFP)  was obtained  from Merck,  Sharpe  and  Dohme Co., 
West Point, Pennsylvania. 
Partially purified Cq esterase inhibitor was supplied by Dr. N. Tamura, Howard Hughes 
Medical Research Institute, Miami. 
EUagic Add.--Ella#c acid was obtained from K and K Laboratories, ~'amalca, New York, 
lot 52062. It was made up in a  1 X  10  --4 z~ solution in Tyrode's buffer. 
Plasma Substrate.--Citrated  fresh human  plasma,  collected in sillconized glassware,  was 
heated to 61°C for 2 hr to destroy the plasma kallikrein system and prevent spontaneous forma- 
tion of bradykinin. The heated plasma was dialyzed overnight against 0.15 M sodium chloride, 
acidified to pH 1.5 for 10 rain at 37°C,  and neutralized, to inactivate kininase. The brady- 
kininogen of the final substrate  (heated, dialyzed, and acidified plasma) was activated by the 
kallikreins but not by Pf/dil and did not spontaneously form bradykinin. 
Preparation of Perfused Lungs.--The guinea pigs were anesthetized with intraperitoneal 
Nembutal  ® (200 mg) and the heart and lungs removed el1 bloc. The trachea was intubated 
and the pulmonary artery cannulated and perfused with Tyrode's solution at 37°C, at a rate 
of 2 mi per minute. The left atrium and ventricle were widely incised (16). Ventilation was 
achieved with Army Emergency Respirator  (lent by Mr. Heintich Straub, Harry Diamond 
Laboratories, Washington, D. C.) which produced an intermittent negative pressure of 10 to 
20 cm of water within a closed chamber into which the heart-lung preparation was suspended, 
with the tracheal cannula open to the air. The lungs were per/used until free of gross blood 
(15 to 20 rain)  and  bovine serum albumln; 2  rag,  was injected into the  pulmonary artery 
cannula. Perfusate was collected at 1 rain intervals and immediately iced and centrifuged in the 
cold. 
Per/usions made in the presence of ethylenediaminetetraacetic acid (EDTA) were performed 
by addition of EDTA to the perfusion fluid (Tyrode's) in a final concentration of 0.005 ~t. 
Per/usions made in the presence of ellagic acid were performed by rapid infusion of 10 ml of 
ellagic acid, 1 X  10  -4 ~r in Tyrode's, into the pulmonary artery cannula after completion of a 
preliminary per/usion with Tyrode's buffer until the lungs were blood-free. 
Sensitization  of Guinea Pigs.--Hartley strain  guinea pigs  (250 to 400  g)  were actively 
sensitized with subcutaneous bovine serum albumin (BSA) 3 wk previously and boosted with 
1 to 2 intradermal injections of BSA at 4-day intervals until a marked Arthus reaction was 
observed; or, were passively sensitized intravenously 18 to 24 hr before use with rabbit anti- 
bovine serum albumin, 0.25 mg antibody nitrogen per animal. The principles of laboratory 
animal care as promulgated by the National Society for Medical Research were observed. 
Bioassay.--Bioassay  of the perfusate was performed by incubation of 0.5 ml samples with 
0.25  ml of plasma substrate,  at 37°C  for 10 mill; the kinin released by this incubation was 
measured by contraction of the isolated estrus rat uterus, according to the method of Eisen 
(17), and compared to contractions obtained with synthetic bradykinin standards. Histamine 
and  a  slow reacting substance  of anaphylaxis  (SRS-A) were assayed  by contraction of the O.  JONASSON  AND  E. L. BECKER  511 
isolated guinea pig ileum, according to the method of Brocldehurst (18). Permeability activity 
was determined in "blued" guinea pigs according to the method of Miles and Wilhelm (19) 
as modified by McConnell et al. (20). 
Inhibition Sludies.  ]Inhibition  of the activity of plasma and lung kallikrein was carried out 
by incubation  of the  enzyme with the inhibitor for  1 hr  at  room temperature.  When  di- 
isopropylphosphofluoridate  (DFP)  was  the inhibitor  being  tested,  the  DFP  was  removed 
prior to bioassay by passage of the sample through a column (1.0 X  20 cm) of Sephadex G-25 
(medium)  (Pharmacia Fine Chemicals, Piscataway, N. J.) immediately before testing. 
Preparative Agar  Electrophoresis.--Agar  electrophoresis  was  performed  as  described  by 
Ovary et al.  (21), on 31/~ X  4 in. glass slides filled with 20 ml of 2% Ionagar (Consolidated 
Laboratories, Inc., Chicago Heights, Illinois) diluted  with equal parts of 0.1 ~t glycine buffer 
at pH 8.6.  A longitudinal well holding 0.3  ml of sample was cut in the center and reference 
sera were placed at either end for immunoelectrophoresis. Electrophoresis was done at 4°C in 
0.05 ~s giycine buffer,  using 40 v for 60 min. Nine longitudinal strips (6 X  0.5 cm) were cut 
out parallel to the center well, and eluted with 0.16 M sodium chloride after freezing and thaw- 
ing one time to break up the agar. 
Gel Filtration.--Fractionation  of whole serum and of kallikrein preparations was carried out 
with gel filtration on columns (1.3 X  45 cm) of Sephadex G-200 (Pharmacia Fine Chemicals). 
Samples were made up in 10% sucrose with 10  mg of Blue Dextran  2000  (Pharmacia  Fine 
Chemicals) as a marker;  1.0 ml samples were applied to the column and eluted with 0.05 x, 
phosphate buffer at 4°C. Fractions of 1.0 mi were collected, and optical density was measured 
at 280 m#. 
Sucrose C,  radienl.--The positions of serum and lung kallikrein on a sucrose density gradient 
of 5 to 20%, were determined using the Spinco Model L ultracentrifuge at 36,000 l~im for 15 
hr at 4°C. Twenty-five fractions of ten drops each were analyzed by bioassay and compared 
to the positions of marker proteins (BSA and human gamma globulin). 
RESULTS 
Release of Kallikrdn 
Time Sequence.--In  vitro anaphylaxis in the actively or passively sensitized 
isolated guinea pig lung was induced by introduction of bovine serum albumin, 
2 mg, into the pulmonary artery. Within 2 min, severe bronchospasm occurred, 
and the lungs remained in a hyperaerated condition. 
As seen in Fig.  1, the perfusate collected immediately before antigen was in- 
jected  contained  little  or no kinin-forming  activity;  perfusate  collected each 
minute  after antigen  contained  increasing  amounts  of kinin-forming  enzyme 
as measured by kinin liberation from plasma substrate. Enzyme levels decreased 
after 6 mill and were barely detectable 15 rain after anaphylaxis. 
Histamine  levels  were  determined  ill  the  perfusate  by  contraction  of  the 
atropinized  guinea  pig  ileum.  In  Fig.  2,  it  is  apparent  that  histamine  was 
released in largest amounts within the first 5 rain following anaphylaxis,  and 
was not released in significant  amounts  after  10 min.  SRS-A,  as  assayed  by 
contraction of the atropinized guinea pig ileum in the presence of antihistamine, 
was released during the first 10 mill after anaphylaxis and decreased in amount 
but was still present after 20 rain. 
Incubation  of  perfusate  with  bradykinin  at  37°C  resulted  in  progressive 512  I~ELEASE OF  KALLIKREIN 
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FIG. 1.  KaUikrein activity in guinea pig lung perfusate during antigen administration. 
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Fro. 2.  Histamine and SRS-A in guinea pig lung perfusate during antigen administration. O.  JONASSON  AND  E.  L.  BECKER  513 
decrease of klnln activity, due to the presence of kininase in the lung perfusate 
(14). This kinlnase activity was decreased significantly by dilution of the per- 
fusate, and was inactivated by acidification of the perfusate. 
TABLE I 
Effect of EDTA on Anapkylacbic Rdease of Histamine,  SRS-A, and Kallikrein by the Isolated 
Perfused Guinea Pig Lung* 
Perfusate 
Control, before antigen. 
2 rain, after antigen. 
4 rain,  "  " 
6 rain,  "  " 
8 rain,  "  " 
i0 rain,  "  " 
12 rain,  "  " 
Histsmine 
No 
EDTA 
0 
20 
20 
23 
20 
4 
3 
EDTA  No  EDTA  EDTA 
0  0 
20  0 
5  0 
3 
5  0 
3 
8  0 
SRS-A  Kallikrein 
No  EDTA  EDTA 
IO  I0 
5O  64 
6O  87 
30  70 
30  6O 
Height of contraction of guinea pig ileum or rat uterus, in millimeters. 
* No histamine,  SRS-A, or kallikrein was released with EDTA alone, in the absence of 
antigen. 
TABLE II 
Effect o/Addition o/10  -4 ~  Ellagic Acid to Fluid Per[using the  Unsensi~ir~t Guinea Pig Lung 
Perfusate  Kinin production 
Control perfusate, before ellagic acid ........................... 
2 rain, after ellagic acid .................................... 
4 rain,  "  "  "  .................................... 
6 mill,  "  "  "  ..................................... 
8 rain,  ' ....  '  .................................... 
10 rain,  "  "  "  ..................................... 
Ellagic acid +  control perfusate ............................... 
EUagic acid alone ............................................. 
Bradykinin, 10 nanograms ..................................... 
2* 
2 
4 
6 
35 
30 
2 
0 
38 
* Height of contraction of rat uterus, in millimeters. 
Effect of EDTA.--Release  of kanikrein from the lung tissue was found to be 
independent of the release of histamine and SRS-A, it not being affected by the 
presence  of  ethylenediaminetetraacetic acid  (EDTA)  in  the  fluid  used  to 
perfuse the lungs. Histamine and SRS-A were  not present in the  recalcified 
perfusate  a/ter  anaphylaxis, when 0.005  ,~  EDTA in Tyrode's solution was 
used to perfuse the lungs (Table I). KaUikrein was present in these perfusates, 514  RELEASE  OF  KALLIKREIN 
in concentrations equal to those of control perfusions using Tyrode's solution 
alone. Bronchospasm was reduced in the lungs receiving EI)TA peffusion. 
Effect of Ellagic Acid.--Table II shows the results of an experiment in which 
ellagic acid was perfused through  unsensitized guinea pig lung.  No kallikrein 
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FIG. 3.  (a) Preparative agar electrophoresis of guinea pig serum kallikrein.  (b) Bioassay of 
eluates from strips 1 to 9 of agar electrophoresis. Rat uterus. 
activity was present in the perfusate of unsensitized lungs prior to the infusion 
of ellagic acid into the pulmonary artery cannula.  Following addition of ellagic 
acid,  kallikrein  activity appeared in the perfusate, reaching  maximal levels at 
8 rain, and declining by 10 min. Addition of eUagic acid in equal amounts to the 
inactive  preliminary  peffusate failed  to  produce  kallikrein  activity.  Ellagic 
acid alone added to the plasma substrate, did not produce kinin. 0. JONASSON AND E. L. BECKER  515 
In a  second experiment, not shown here,  the same  results  were  obtained 
with infusion of ellagic acid, with the exception that, when ellagic acid 10  -'4 ~r 
was incubated with the control perfusate, k{nln was produced when plasma 
substrate was added. Again, neither the control peffusate nor ellagic acid alone 
had kallikrein activity. 
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FIG. 4.  (a)  Preparative agar eleetrophoresis  of guinea pig lung perfusate.  (b) Bioassay of 
eluates from strips  1 to 9 of agar eleetrophoresis. 
Properties o/Lung Kallikrein 
Certain properties of guinea pig lung kallikrein have been found identical to 
those of guinea pig serum kallikrein. 
Electropkoretic Mobility.--Guinea  pig  serum  kanikrein and lung peffnsate 
were  subjected to preparative  agar  electrophoresis  (Figs.  3  and 4).  Eluates 
from the  areas  of slow gamma globulin mobility only, were active in  each 
instance.  This area corresponded to a  weak precipitin band in the adjacent 
immunoelectrophoresis patterns. 516  RELEASE O~ KALLIKI%EIN 
Size.--Guinea  pig serum kaUikrein and lung perfusate were subjected to gel 
filtration on columns of Sephadex  G-200.  Activity came off (with a  tenfold 
dilution) in two areas, identical in each sample. The first area, tubes 45 to 55, 
corresponded to the dip between macroglobulins and 7S globulins. The second 
area of activity, tubes 70 to 80, was unexpected and appeared in each sample 
in the dip immediately prior to the albumin peak (Fig. 5). Further characteriza- 
tion of this peak was not carried out. 
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Fro. 5. Gel filtration on Sephadex G-200 (45 X 1.3 cm). Note two separate peaks of kall/- 
krein activity; tubes 45 to 55, and tubes 70 to 80. Sample size, 1 ml. 
Sucrose density gradient ultracentrifugafion of serum kallikrein and of lung 
kallikrein each yielded activity over a  broad area without distinguishing two 
peaks of activity as had been noted with gel filtration. The broad area of activ- 
ity began in samples before the human gamma globulin marker protein, and 
extended to but did not include the samples containing the bovine serum al- 
bumin  marker  protein.  This  broad  distribution  of  kallikrein  activity was 
compatible with the molecular size  heterogeneity of kaUikrein found by gel 
filtration. 
Inhibition of Actldty.-- 
Soybean trypsin inhibitor (SBTI): Samples of lung perfusate were incubated 
with SBTI, 50 #g per ml of perfusate, for 1 hr at room temperature, and were O.  JONASSON AND  E.  L.  BECKER  517 
then added to plasma substrate. Bioassay with the rat uterus (Fig. 6), demon- 
strated complete inhibition of activity of the lung perfusate by SBTL 
These results were confirmed with assay of permeability activity in "blued" 
guinea pigs. As seen in Table III, permeability activity of bradykinin was not 
I g 
I  I  I  I 
A  B  C  D  E 
Fro. 6. Inhibition of lung peffusate with soybean trypsin inhibitor (SBTI). Substrate: 
human plasma (heated, dialyzed, and acidified). Rat uterus. (A) Bradykinin, 5 nanograms; 
(B) perfusate, 1 min, 0.5 ml,  +  SBTI, 50 nanograms; (C) perfusate, 1 rain, 0.5 ml; (D) 
peffusate, 4 rain, 0.5 ml; and (E) peffusate, 4 rain, 0.5 ml, +  SBTI, 50 nanograms. 
TABLE  III 
Permeability Act~t~i~y 
Bradykinin 1.0 p,  RJml  Perfusate 
Dilutions 
SBT150/zg 
1:2 
1:4 
1:8 
1:16 
1:32 
1:64 
1:128 
Tyrode's 
SBT150 .ug 
11"  11 
10  9.5 
10  8 
9.5  8.5 
9  7 
6  6.5 
3  0 
4  3 
10 
8.5 
0 
0 
0 
0 
0 
3 
* Diameter of blue spot on skin of blued guinea pig in millimeters;  0.2 ml volumes. 
affected by SBTI, while permeability activity of lung perfusate kallikrein was 
abolished by SBTI. 
Diisopropylphosphofluoridate  (DFP):  Samples of lung perfusate were incu- 
bated for 1 hr at room temperature with DFP at concentrations of 1.0 X  10  -8 
and 5.0 X  10  -4 5. After removal of DFP, bioassay using the rat uterus (Fig. 7) 
demonstrated incomplete inhibition by the lower concentration of DFP,  and 
complete inhibition by the higher concentration of DFP. 
C'I  esterase inhibitor:  Varying volumes of lung perfusate and of guinea pig 518  RELEASE  OF  KALLIK_REIN 
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FIG. 8.  Inhibition  of guinea pig serum kallikrein and lung peffusate by C'I esterase inhibi- 
tor. Volume of inhibitor constant (0.5 ml); volume of kallikrein sample varied from 0.1 to 0.5 
ml. Incubation for 1 hr at 25°C. 
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F~G. 7.  Inhibition of lung peffusate with diisopropylphosphofluoridate (DFP).  Substrate: 
human plasma (heated, dialyzed, and acidified).  Rat uterus.  (A) Bradykinin, 2 nanograms; 
(B) bradykinin, 0.5 nanograms; (C) perfusate, 2 rain, 0.5 ml, incubated at 25°C for 1 hr, then 
passed through Sephadex  (;-25; (D) perfusate, 2 rain, 0.5 ml, incubated with DFP (1.0  X 
10aM) at 25°C for 1 hr, then passed through Sephadex  G-25; (E) perfusate, 2 rain, 0.5 ml, 
incubated with DFP (5.0 X  10  -4 x() at 25°C for 1 hr, then passed through Sephadex  G-25. O.  JONASSON  AND  E.  L.  BECKER  519 
serum kallikrein were incubated at room temperature for 1 hr with 0.5 ml of 
guinea pig C'I esterase inhibitor. Bioassay with the rat uterus (Fig. 8) revealed 
progressive inhibition  of enzyme activity of serum  and  lung kallikrein  with 
higher concentrations of inhibitor. Within the broad limits of this experiment, 
it was also apparent that the degree of increase of inhibition of serum and lung 
kallikrein  with each decreasing  concentration of enzyme, was similar. 
DISCUSSION 
These experiments confirm  the reports of Brocklehurst and Lahiri,  that the 
antigen-antibody reaction is associated with the release  of kallikrein  into the 
effluent of the perfused guinea pig lung (14). In all properties we have studied, 
the lung kallikrein  is indistinguishable from plasma kallikrein.  Soybean trypsin 
inhibitor  and DFP in the same concentrations inhibit  the lung  kallikrein  to 
apparently the same degree as guinea pig plasma kallikrein.  The inhibition of 
guinea pig lung and plasma ka|llkrein by a preparation containing guinea pig 
Crl esterase inhibitor, extends to this species the findings of Kagan that human 
C'I  esterase inhibitor inactivates human plasma kallikrein  (22).  C'I  esterase 
inhibitor is, so far as it is known, rather specific, inhibiting only C'I esterase, 
kallikrein,  and Pf/dil; the rather closely related enzymes, plasmin and throm- 
bin, are not affected. 
Not only are the kallikreins  of guinea pig lung and plasma similar  in their 
susceptibility to inhibitors, but they are also similar in those physical properties 
which we have  studied.  On electrophoresis,  both have mobility in  the slow 
gamma  region.  When  subjected to  gel  filtration  on  a  column  of  Sephadex 
G-200,  the plasma  and lung preparations  each gave two peaks of kallikrein 
activity in identical areas; one corresponding to a molecular weight less than the 
macroglobulins  but  greater  than  7S  gamma  globulin,  and  the  other  corre- 
sponding to a molecular weight less than the 7S gamma globulin but somewhat 
greater than albumin. 
Both peaks contained  activity of the kallikrein  type as defined by kinin 
production from heated plasma (which  is not capable of activation by Pf/dil 
or enzymes other than kallikrein in the activation sequence of kinin).  These 
results further emphasize  the similarity of lung and plasma kallikrein,  and also 
reveal a completely unexpected heterogeneity in molecular size. An investiga- 
tion of this heterogeneity is under way in our laboratory. 
An unequivocal conclusion as to the relationship of lung and plasma kallikrein 
would be possible only after a much more extensive and detailed comparison 
than was attempted here. Nevertheless, the similarities in the various properties 
of the two kallikreins  disclosed by the present  study suggests that  the kinln- 
forming activity from the two sources is due to the same enzyme. 
The acceptance of the hypothesis that the kallikreins  of lung and plasma are 
the same immediately raises the question of the source of these enzymes. It is 
possible that the lung kallikrein  is derived from residual plasma remaining  in 520  RELEASE  OF  KALLIK.R_EIN 
the perfused lung system, although it seems unlikely that  the enzyme could 
have been present in measurable quantities in the small  amounts of plasma 
present after the extensive perfusion. It is more likely that the kallikreinogen 
has been adsorbed from the plasma on to the endothelial cells or other pul- 
monary  tissues,  and  is  activated  and  released  during  the  antigen-antibody 
reaction. Alternatively, the lung may be a source of kanikrein,  and the kalli- 
krein found in the perfusate as well as that found in plasma might have come 
directly from this tissue. Exploration of these possibilities  must await purifica- 
tion of the kaUikreins beyond what has been presently attempted. 
EDTA has  no  effect on  the  activation  of lung kallikrein  by an  antigen- 
antibody reaction, although it completely blocks the release  of histamine and 
SRS-A.  The mechanisms of immune activation of kallikrein  and of histamine 
and SRS-A are obviously different; the mechanism of the first apparently does 
not invlove a cation-dependent step, whereas,  release of the two latter factors 
does. The insensitivity to EDTA of the activation of lung kallikrein  is, however, 
in accord with the findings of Margolis and Bishop (23) that in human plasma, 
kinin  formation  by glass  activation  of  the  kallikrein  system  occurs  in  the 
presence of 0.01 xf EDTA.  Also,  Armstrong et al.  (24)  have observed kinin 
formation  in  human  plasma  in  the presence  of  citrate.  Thus,  to  the  other 
similarities  between lung and plasma kallikrein already described, one can add 
that activation of either kallikrein  does not involve a cation-dependent step. 
Ratnoff has reported that derivatives of gallic  acid, especially  ellagic acid, 
will activate Hageman factor in plasma, causing an acceleration of clotting (25), 
and the appearance of permeability activity (26). There is good evidence that in 
plasma  the  formation  of  kallikrein  from  prokallikrein  involves  the  initial 
activation  of I-Iageman  factor  (2).  Therefore,  from  several viewpoints it  is 
significant  that active kallikrein  appears in the perfusate of unsensitized lungs 
following the infusion of ellagic acid into the pulmonary artery. Another point 
of similarity between lung and plasma kallikrein  is brought out, and it is sug- 
gested that a system of kaUikrein activation similar to that present in plasma is 
also  present  in  perfused lung.  This  in  turn  suggests,  although  it  does not 
demand, the working hypothesis that the initiating event in the activation of 
kallikrein  by an antigen-antibody reaction is the activation of Hageman factor. 
SUMMARY 
An antigen-antibody reaction occurring in the perfnsed sensitized  guinea pig 
lung, has been demonstrated to release kallikrein,  a proteolytic enzyme related 
to the formation of kinins.  This lung kallikrein  is similar  to plasma kallikrein 
in all properties studied, including  susceptibility to the same inhibitors, electro- 
phoretic mobility, and heterogeneity in molecular size. 
The release  of kallikrein  during anaphylaxis in the guinea pig lung occurs in 
the  presence  of  ethylenediaminetetraacetate.  Perfusion  of  ellagic  acid  into 0.  JONASSON  AND  E.  L.  BECKER  521 
nonsensitized lungs will also release kallikrein, presumably through activation 
of Hageman factor. On the basis of these findings the hypothesis is suggested 
that the kallikrein in periused lung activated by the antigen-antibody reaction 
is,  in fact, plasma kallikrein. It is further suggested that activation of such 
kallikrein by the antigen-antibody reaction proceeds through Hageman factor. 
Guinea pig C'1 esterase was kindly supplied by Dr. N. Tamura of the Howard Hughes 
Medical Research Institute, Miami, Florida. 
The sucrose density studies were performed  with the help of Dr. John Wohlheiter. 
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